Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11504897 | 0.75 | LMNA (0.32) | LMNAMAPTTSHRMAPK1RECQL | |
| SCHEMBL9862354 | 0.71 | LMNA (0.37) | LMNAMAPTTSHRMAPK1RECQL | |
| SCHEMBL2826604 | 0.71 | LMNA (0.37) | LMNAMAPTTSHRMAPK1RECQL | |
| SCHEMBL221185 | 0.71 | LMNA (0.37) | LMNAMAPTTSHRMAPK1RECQL | |
| SCHEMBL9862355 | 0.71 | LMNA (0.37) | LMNAMAPTTSHRMAPK1RECQL | |
| SCHEMBL5445786 | 0.71 | LMNA (0.30) | LMNAMAPTTSHRMAPK1RECQL | |
| SCHEMBL3504556 | 0.71 | LMNA (0.30) | LMNAMAPTTSHRMAPK1RECQL | |
| SCHEMBL1962622 | 0.71 | LMNA (0.30) | LMNAMAPTTSHRMAPK1RECQL | |
| SCHEMBL8241582 | 0.71 | LMNA (0.37) | LMNAMAPTTSHRMAPK1RECQL | |
| SCHEMBL17476402 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183394-B2 | Protease inhibitor precursor synthesis | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2012-05-22 | — | — | US | disclosed |
| US-20120041215-A1 | PROTEASE INHIBITOR PRECURSOR SYNTHESIS | JANSSEN SCIENCES IRELAND UC (IE) | 2012-02-16 | — | — | US | disclosed |
| US-8067463-B2 | Protease inhibitor precursor synthesis | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-11-29 | — | — | US | disclosed |
| EP-1856125-B1 | PROTEASE INHIBITOR PRECURSOR SYNTHESIS | TIBOTEC PHARM LTD (IE) | 2009-08-26 | — | — | EP | disclosed |
| US-20090054668-A1 | Protease inhibitor precursor synthesis | JANSSEN SCIENCES IRELAND UC (IE) | 2009-02-26 | — | — | US | disclosed |
| EP-1373325-B1 | LATENT METALLOCENE CATALYST SYSTEMS FOR OLEFIN POLYMERIZATION | INEOS USA LLC (US) | 2008-03-19 | — | — | EP | disclosed |
| EP-1856125-A1 | PROTEASE INHIBITOR PRECURSOR SYNTHESIS | Tibotec Pharmaceuticals Ltd. (IE) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006089942-A1 | PROTEASE INHIBITOR PRECURSOR SYNTHESIS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2006-08-31 | — | — | WO | disclosed |
| US-6998449-B2 | Latent metallocene catalyst systems for olefin polymerization | BP CORPORATION NORTH AMERICA (US) | 2006-02-14 | — | — | US | disclosed |
| EP-1373325-A2 | LATENT METALLOCENE CATALYST SYSTEMS FOR OLEFIN POLYMERIZATION | BP Corporation North America Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2003025023-A2 | LATENT METALLOCENE CATALYST SYSTEMS FOR OLEFIN POLYMERIZATION | BP CORPORATION NORTH AMERICA INC. (US) | 2003-03-27 | — | — | WO | disclosed |
| US-20030054943-A1 | Latent metallocene catalyst systems for olefin polymerization | BARCLAYS BANK PLC, AS SECURITY AGENT (GB) | 2003-03-20 | — | — | US | disclosed |
| US-4217284-A | Process for preparation of optically pure lactones from monoesters of cis-cyclopentenediol | KOWA COMPANY LTD. (JP) | 1980-08-12 | — | — | US | disclosed |
| US-4170596-A | Novel monoesters of cis-cyclopentenediol, process for preparation thereof, and process for preparation of lactones from the monoesters | KOWA COMPANY, LTD. | 1979-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054668-A1 | Protease inhibitor precursor synthesis | SPINT2, PREP, PEPD | LMNA 1553/4885MAPT 2403/4885TSHR 4347/4885 |
| US-20120041215-A1 | PROTEASE INHIBITOR PRECURSOR SYNTHESIS | SPINT2, PREP, PEPD | LMNA 1553/4885MAPT 2403/4885TSHR 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.